Literature DB >> 1647169

The 5-HT receptor--G-protein--effector system complex in depression. I. Effect of glucocorticoids.

K P Lesch1, B Lerer.   

Abstract

Hormonal modulation of neurotransmission emerged as a concept from the recognition that adrenocortical steroids exert profound effects at the level of receptors, G-proteins and effector units. G-proteins, a family of guanine nucleotide binding regulatory components that couple neurotransmitter receptors to various types of intracellular effector systems, appear to be a key target of glucocorticoid (GC) action in the CNS. It is thought that Gs/Gi mediates stimulation/inhibition of adenylate cyclase (AC system), which forms cyclic AMP as second messenger, while receptors stimulating phospholipase C do so through Go to produce two second messengers, inositol 1,4,5-triphosphate and diacylglycerol (PI system). Recent evidence suggests that GC increase Gs alpha-and decrease Gi alpha-protein subunit expression without affecting Go alpha. Activation of central pre- and postsynaptic 5-HT1A receptors which are linked to the Gi-AC complex, induces hypothermia and ACTH/cortisol release in rodents and humans. Compared with controls, patients with a major depressive disorder exhibit increased basal cortisol secretion associated with decreased hypothermic and ACTH/cortisol responses. The attenuated neuroendocrine and thermoregulatory response to 5-HT1A receptor activation may reflect a GC-dependent feedback inhibition of the hypothalamic-pituitary-adrenal (HPA) system and subsensitivity of the presynaptic 5-HT1A-Gi-AC complex function. Differential regulation of 5-HT1A and 5-HT2 function leading to a relative 5-HT2-Go-PI complex supersensitivity may maintain HPA hyperactivity during the course of depression. These findings corroborate recent reports that GC, via GC-GC receptor (GR) complex activated promotion of gene transcription, modify the expression 5-HT1A-coupled Gi (but not 5-HT2-coupled Go) resulting in altered sensitivity of 5-HT1A-mediated signal transduction and further support the hypothesis of a differential regulation of 5-HT1A and 5-HT2 receptor function and a GC-GR/5-HT1A-G-protein--effector system-related abnormality in depression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647169     DOI: 10.1007/bf01249105

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  74 in total

Review 1.  Serotonin receptors: clinical implications.

Authors:  R A Glennon
Journal:  Neurosci Biobehav Rev       Date:  1990       Impact factor: 8.989

2.  Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects.

Authors:  R C Arora; H Y Meltzer
Journal:  Am J Psychiatry       Date:  1989-06       Impact factor: 18.112

3.  Molecular characterization of a functional cDNA encoding the serotonin 1c receptor.

Authors:  D Julius; A B MacDermott; R Axel; T M Jessell
Journal:  Science       Date:  1988-07-29       Impact factor: 47.728

Review 4.  Psychiatric implications of altered limbic-hypothalamic-pituitary-adrenocortical activity.

Authors:  F Holsboer
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

5.  A neuroendocrine study of 5HT function in depression: evidence for biological mechanisms of endogenous and psychosocial causation.

Authors:  J F Deakin; I Pennell; A J Upadhyaya; R Lofthouse
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Paraventricular nucleus serotonin mediates neurally stimulated adrenocortical secretion.

Authors:  S Feldman; N Conforti; E Melamed
Journal:  Brain Res Bull       Date:  1987-02       Impact factor: 4.077

7.  Increased serotonin2 (5-HT2) receptor binding as measured by 3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patients.

Authors:  R C Arora; H Y Meltzer
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

8.  Altered responses to serotonergic agents in Fawn-Hooded rats.

Authors:  G A Gudelsky; J I Koenig; H Y Meltzer
Journal:  Pharmacol Biochem Behav       Date:  1985-03       Impact factor: 3.533

9.  Central serotonergic responses and behavioural adaptation to repeated immobilisation: the effect of the corticosterone synthesis inhibitor metyrapone.

Authors:  G A Kennett; S L Dickinson; G Curzon
Journal:  Eur J Pharmacol       Date:  1985-12-17       Impact factor: 4.432

10.  Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion.

Authors:  G Di Renzo; S Amoroso; M Taglialatela; L Canzoniero; V Basile; A Fatatis; L Annunziato
Journal:  Eur J Pharmacol       Date:  1989-03-21       Impact factor: 4.432

View more
  5 in total

1.  Antiglucocorticoids as Treatments for Depression : Rationale for Use and Therapeutic Potential.

Authors:  L H Price; R T Malison; C J McDougle; G H Pelton
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

Review 2.  Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.

Authors:  Antonella Cardinale; Francesca R Fusco
Journal:  CNS Neurosci Ther       Date:  2018-03-03       Impact factor: 5.243

Review 3.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

4.  [3H]paroxetine and [3H]citalopram as markers of the human brain 5-HT uptake site: a comparison study.

Authors:  B Arranz; J Marcusson
Journal:  J Neural Transm Gen Sect       Date:  1994

5.  Time course of the effects of adrenalectomy and corticosterone replacement on 5-HT1A receptors and 5-HT uptake sites in the hippocampus and dorsal raphe nucleus of the rat brain: an autoradiographic analysis.

Authors:  S M Tejani-Butt; D M Labow
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.